乳腺癌肝寡转移CT引导HDR近距离放疗的生存与毒性:BRALIBREST多中心真实世界研究
BRALIBREST真实世界多中心研究纳入107例乳腺癌肝寡转移患者,评估CT引导HDR近距离放疗的疗效与耐受性。中位OS为37个月,2年OS率60%,中位PFS、LRC、mPFS分别为13、19、15个月,疾病控制率6个月93%、12个月98%。仅观察1-2级急性毒性,8%晚期3级肝毒性。
要点
- 中位OS 37个月,2年OS率60%,中位PFS 13个月,LRC 19个月
- 疾病控制率从6个月93%升至12个月98%,ORR从63%升至85%
- GTV 90%接受≥25 Gy可使死亡风险减半
核心结论
- HDR近距离放疗对经选择的乳腺癌肝寡转移患者是一种有效的转移导向治疗。
研究设计与样本
- 多中心真实世界研究,纳入107例乳腺癌肝寡转移患者,定义为肝转移灶≤5个、WHO体能状态<3、肿瘤直径<10 cm。
- 排除肿瘤位置无法放置施源器或无法实现CT引导HDR-BT充分剂量覆盖的患者。
- 中位处方剂量20 Gy(范围15-25 Gy),61%患者治疗单个病灶,39%治疗多个病灶。
主要发现
- 中位OS为37个月,2年OS率60%;中位PFS、LRC、mPFS和后续系统治疗线数自由时间分别为13、19、15和22个月。
- 疾病控制率从6个月93%改善至12个月98%,ORR从63%升至85%。
- 单因素分析中,重复和诱导性寡转移疾病预测更优OS,而肝外扩散、肝脏体积>10 cm3和病灶直径>4 cm为不良因素。
- GTV 90%接受≥25 Gy可使死亡风险减半。
- 仅观察到1-2级急性毒性,无≥3级事件,8%出现晚期3级肝毒性。
关键数值与推荐
- 寡转移性乳腺癌定义:肝转移灶≤5个、WHO体能状态<3、肿瘤直径<10 cm。
- 中位处方剂量20 Gy(15-25 Gy)。
- GTV 90%接受≥25 Gy与死亡风险减半相关。
- 疾病控制率6个月93%、12个月98%;ORR 6个月63%、12个月85%。
- 晚期3级肝毒性发生率8%,无≥3级急性毒性。
临床怎么用
- 对于经选择的乳腺癌肝寡转移患者(≤5个肝转移灶、WHO PS<3、肿瘤直径<10 cm),可考虑CT引导HDR近距离放疗作为转移导向治疗。
- 治疗计划中应尽量使GTV 90%接受≥25 Gy,以可能降低死亡风险。
- 需关注晚期3级肝毒性(8%),治疗前评估肿瘤位置以确保施源器可放置和剂量充分覆盖。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate efficacy and tolerability of high-dose-rate brachytherapy (HDR-BT) for breast-cancer (BC) liver oligometastases. STUDY DESIGN: We included patients with oligometastatic breast cancer, defined as having ≤ 5 liver metastases, WHO performance status <3, tumor diameter <10 cm. Patients were excluded if tumor location prevented applicator placement or adequate dosing of CT-guided HDR-BT. End-points were overall survival (OS), progression-free survival (PFS), locoregional control (LRC), modified PFS (mPFS), freedom from subsequent systemic-therapy line and radiological response - disease control rate and objective response rate (ORR). Univariate (UVA) and multivariate (MVA) Cox models explored clinicopathologic and dosimetric predictors. RESULTS: A total of 107 patients were included; 61 % were treated for a single lesion, and 39 % for multiple. The median prescribed dose was 20 Gy (15-25 Gy). The median OS was 37 months (2-year: 60 %). Median PFS, LRC, mPFS, and freedom from subsequent systemic-therapy were 13, 19, 15, and 22 months. Disease control rate improved from 93 % at 6 months to 98 % at 12, while ORR rose from 63 % to 85 %. On UVA, repeat and induced oligometastatic disease predicted superior OS, while extrahepatic spread, liver volume >10 cm3, and lesion diameter >4 cm were adverse. Delivering ≥25 Gy to 90 % of GTV halved the risk of death. Only grade 1-2 acute toxicities were observed; no grade ≥3 events, with 8 % late grade 3 hepatic toxicity. CONCLUSION: HDR-BT appears to be an effective metastasis-directed therapy for selected patients with BC liver oligometastases.
引用
- Bilski M, Kuncman Ł, Orzechowska M, et al. Survival outcomes and toxicity profile after CT-guided HDR brachytherapy (interventional radiotherapy) for liver oligometastases in breast cancer patients: The BRALIBREST real world multicenter study. Radiother Oncol. 2025. PMID: 41238080. doi:10.1016/j.radonc.2025.111280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。